Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Nov 22;79(5):1242-1257. doi: 10.1093/cid/ciae228. Clin Infect Dis. 2024. PMID: 38663013
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.
Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group. Hatleberg CI, et al. J Int AIDS Soc. 2018 Mar;21(3):e25083. doi: 10.1002/jia2.25083. J Int AIDS Soc. 2018. PMID: 29509305 Free PMC article.
Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E, Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord. Podlekareva DN, et al. Lancet HIV. 2016 Mar;3(3):e120-31. doi: 10.1016/S2352-3018(15)00252-0. Epub 2016 Feb 2. Lancet HIV. 2016. PMID: 26939735 Free article.
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Mocroft A, et al. Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17. Lancet HIV. 2016. PMID: 26762990 Clinical Trial.
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Mocroft A, et al. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25826420 Free PMC article.
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. Bruyand M, et al. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523. J Acquir Immune Defic Syndr. 2015. PMID: 25763785
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
30 results